These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 16896008

  • 1. ErbB-3 predicts survival in ovarian cancer.
    Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.
    J Clin Oncol; 2006 Sep 10; 24(26):4317-23. PubMed ID: 16896008
    [Abstract] [Full Text] [Related]

  • 2. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S, Ilić Forko J, Babić D, Sundov D, Kuret S, Andelinović S.
    Croat Med J; 2003 Aug 10; 44(4):429-34. PubMed ID: 12950146
    [Abstract] [Full Text] [Related]

  • 3. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
    Micke P, Basrai M, Faldum A, Bittinger F, Rönnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG.
    Clin Cancer Res; 2003 Jan 10; 9(1):188-94. PubMed ID: 12538468
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 10; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 5. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
    Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D.
    Cancer Res; 2001 Nov 01; 61(21):7811-8. PubMed ID: 11691797
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.
    J Clin Oncol; 2006 Nov 01; 24(31):4998-5004. PubMed ID: 17075118
    [Abstract] [Full Text] [Related]

  • 7. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J.
    Gynecol Oncol; 2007 Nov 01; 107(2):266-73. PubMed ID: 17698176
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB, Iversen OE, Akslen LA.
    Clin Cancer Res; 1998 Nov 01; 4(11):2779-85. PubMed ID: 9829742
    [Abstract] [Full Text] [Related]

  • 11. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
    Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB.
    Anticancer Res; 2000 Nov 01; 20(2B):1061-7. PubMed ID: 10810398
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S.
    J Clin Oncol; 2006 Sep 10; 24(26):4245-53. PubMed ID: 16963728
    [Abstract] [Full Text] [Related]

  • 14. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
    Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267
    [Abstract] [Full Text] [Related]

  • 15. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.
    Clin Cancer Res; 2008 Mar 15; 14(6):1726-33. PubMed ID: 18347173
    [Abstract] [Full Text] [Related]

  • 16. High expression of HER3 is associated with a decreased survival in gastric cancer.
    Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K.
    Clin Cancer Res; 2008 Dec 01; 14(23):7843-9. PubMed ID: 19047113
    [Abstract] [Full Text] [Related]

  • 17. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 18. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C.
    J Natl Cancer Inst; 2005 Apr 20; 97(8):560-6. PubMed ID: 15840878
    [Abstract] [Full Text] [Related]

  • 19. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A, Melanoma Group of the European Organization for Research and Treatment of Cancer.
    J Natl Cancer Inst; 2006 Apr 05; 98(7):472-82. PubMed ID: 16595783
    [Abstract] [Full Text] [Related]

  • 20. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA.
    J Clin Oncol; 2011 Aug 01; 29(22):3030-6. PubMed ID: 21709195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.